Tesamorelin Review 2026 — Clinical Evidence & Usage
A 2022 meta-analysis published in Obesity Reviews found that visceral adipose tissue reduction with tesamorelin averaged 15.2% at 26 weeks. A magnitude of effect that diet and exercise interventions rarely achieve in isolation, particularly in patients with HIV-associated lipodystrophy. Yet most discussions of this growth hormone-releasing hormone (GHRH) analog skip the mechanism entirely and jump straight to dosing protocols, leaving users confused about why reconstitution errors, injection timing, and receptor desensitization matter as much as the peptide itself.
We've guided research teams and individual users through tesamorelin protocols since 2019. The gap between effective use and wasted compounds comes down to three procedural details most suppliers never mention: bacteriostatic water pH compatibility, subcutaneous injection site rotation to prevent lipohypertrophy, and the 90-day receptor sensitivity threshold that determines whether you maintain results or plateau hard.
What makes tesamorelin effective for visceral fat reduction in 2026?
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates endogenous growth hormone (GH) secretion from the anterior pituitary gland, leading to increased IGF-1 levels and preferential reduction of visceral adipose tissue (VAT). The metabolically active fat surrounding internal organs. Clinical trials demonstrate 15–20% VAT reduction at 26 weeks with 2mg daily subcutaneous dosing, making it one of the few FDA-approved pharmacological interventions specifically indicated for abdominal fat in HIV lipodystrophy. The mechanism targets visceral fat through GH-mediated lipolysis without the systemic GH elevation that causes peripheral side effects common with exogenous growth hormone therapy.
Most users assume tesamorelin works like other fat-loss compounds. Appetite suppression, thermogenesis, or caloric partitioning. It doesn't. Tesamorelin activates GHRH receptors in the pituitary, triggering a pulsatile release of endogenous growth hormone that mimics the body's natural circadian GH rhythm. This pulsatile pattern is why tesamorelin produces visceral fat loss without the joint pain, carpal tunnel syndrome, or glucose dysregulation seen with continuous exogenous GH administration. The rest of this tesamorelin review 2026 covers exactly how receptor activation works, what dosing errors negate efficacy entirely, and what preparation mistakes turn a $300 vial into expensive saline.
Tesamorelin Mechanism of Action and Clinical Evidence
Tesamorelin functions as a growth hormone-releasing hormone (GHRH) receptor agonist. Meaning it binds to GHRH receptors on somatotroph cells in the anterior pituitary gland and triggers the release of endogenous growth hormone into circulation. This is mechanistically different from exogenous growth hormone (which replaces endogenous production) or growth hormone secretagogues like MK 677 (which act on ghrelin receptors). Tesamorelin preserves the body's natural pulsatile GH secretion pattern, which is why it produces visceral fat reduction without the insulin resistance and edema common to continuous GH elevation.
The GHRH receptor is a G-protein-coupled receptor (GPCR) that activates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP) levels. Elevated cAMP triggers protein kinase A (PKA) activation, which phosphorylates transcription factors that upregulate GH gene expression and promote GH vesicle exocytosis from somatotrophs. Tesamorelin has a half-life of approximately 26–38 minutes in plasma, but the downstream effects. Elevated GH and subsequently elevated IGF-1. Persist for hours after administration. This creates a transient GH pulse similar to physiological secretion, which occurs in 6–10 pulses per day in healthy adults, predominantly during deep sleep.
Clinical evidence for tesamorelin comes primarily from two Phase 3 randomized controlled trials published in The Lancet in 2010. The trials enrolled 806 HIV-positive patients with abdominal obesity and measured visceral adipose tissue (VAT) using CT imaging at baseline and 26 weeks. Patients receiving 2mg daily subcutaneous tesamorelin demonstrated mean VAT reduction of 15.2% versus 4.5% placebo. A statistically significant difference (p<0.001). Importantly, subcutaneous adipose tissue (SAT) did not decrease proportionally, indicating preferential VAT loss. This selectivity is attributed to the higher density of GH receptors in visceral adipocytes compared to subcutaneous fat depots.
A 26-week extension study published in AIDS in 2012 evaluated durability of response. Patients who continued tesamorelin maintained VAT reductions, but those who discontinued experienced partial VAT regain. Approximately 40% of lost VAT returned within 26 weeks off-treatment. This suggests tesamorelin is not a one-time intervention but a maintenance therapy for sustained visceral fat control. IGF-1 levels increased by approximately 35–50% during treatment and returned to baseline within 2–4 weeks of discontinuation, consistent with the peptide's mechanism of endogenous GH stimulation rather than receptor-independent action.
Adverse events in clinical trials were predominantly injection site reactions (erythema, pruritus) in 20–30% of patients, and transient hyperglycemia or elevated HbA1c in approximately 8% of participants. One critical finding: tesamorelin did not produce the glucose dysregulation magnitude seen with exogenous GH therapy. Mean fasting glucose increased by approximately 4–6 mg/dL. Statistically significant but clinically modest. Patients with pre-existing diabetes or impaired glucose tolerance showed higher rates of worsening glycemic control, making baseline and periodic HbA1c monitoring essential in this population.
Real Peptides offers Tesamorelin Peptide as research-grade lyophilized powder synthesized to >98% purity with exact amino-acid sequencing, manufactured in small-batch runs to ensure consistency across vials. Our synthesis process includes HPLC verification at every production stage, guaranteeing the peptide integrity required for reproducible research outcomes. You can also explore our Tesamorelin Ipamorelin Growth Hormone Stack for researchers investigating synergistic GH secretagogue protocols.
Reconstitution Protocol and Storage Requirements
Tesamorelin arrives as lyophilized powder. A freeze-dried crystalline form that remains stable at room temperature for short durations but must be stored at −20°C for long-term stability. Lyophilization removes water, preventing peptide bond hydrolysis that would degrade the molecule. Once water is reintroduced through reconstitution, the peptide becomes susceptible to temperature-dependent degradation, bacterial contamination, and pH-related structural changes. Reconstitution errors are the single most common reason users report "tesamorelin didn't work". The peptide was denatured before the first injection.
Bacteriostatic water is the required reconstitution solvent. Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits bacterial growth in multi-dose vials by disrupting bacterial cell membranes. Standard sterile water lacks this preservative, making it unsuitable for multi-dose protocols. Bacteria introduced during the first draw proliferate by the second or third injection. Real Peptides supplies pharmaceutical-grade Bacteriostatic Water tested for endotoxin levels and pH stability, ensuring compatibility with peptide reconstitution requirements.
Reconstitution steps:
Remove tesamorelin vial from −20°C storage and allow it to reach room temperature (15–20 minutes). Condensation forming inside a cold vial during reconstitution introduces water droplets that create uneven mixing.
Swab the rubber stopper on both the tesamorelin vial and bacteriostatic water vial with an alcohol prep pad. Allow 30 seconds for complete alcohol evaporation. Residual alcohol in the vial denatures peptides on contact.
Draw the appropriate volume of bacteriostatic water into a sterile syringe. For a 2mg tesamorelin vial, 2mL of bacteriostatic water creates a 1mg/mL concentration, making daily 2mg dosing straightforward (2mL per injection). Some users prefer 1mL total volume for smaller injection volumes, yielding 2mg/mL concentration.
Inject bacteriostatic water slowly down the inside wall of the tesamorelin vial. Never spray directly onto the lyophilized powder. Direct spray causes foaming and mechanical shearing of peptide bonds. Let the water slide down the vial wall and reconstitute the powder passively.
Swirl gently. Do not shake. Shaking introduces air bubbles and mechanical stress that denature peptides. Reconstitution should take 2–3 minutes of gentle swirling until the solution is clear. Cloudiness or particulate matter indicates incomplete reconstitution or contamination. Discard the vial.
Label the vial with reconstitution date. Once reconstituted, tesamorelin must be refrigerated at 2–8°C and used within 28 days. Beyond 28 days, peptide degradation accelerates even under refrigeration.
Storage after reconstitution: refrigerate at 2–8°C in the original vial. Do not freeze reconstituted peptide. Ice crystal formation during freezing causes irreversible structural damage. Any temperature excursion above 8°C for more than 2 hours significantly reduces potency. If you're traveling, a portable medication cooler (like the FRIO wallet used for insulin) maintains 2–8°C for 36–48 hours without refrigeration using evaporative cooling.
The biggest mistake users make isn't contamination. It's injecting air into the vial while drawing solution. Each time you draw from a multi-dose vial, you must equalize pressure by injecting an equivalent volume of air before withdrawing the solution. Failure to do this creates negative pressure inside the vial, which pulls contaminants backward through the needle on subsequent draws. This is why proper aseptic technique matters more after reconstitution than during it.
Dosing, Injection Technique, and Timing Considerations
Clinical trials establishing tesamorelin efficacy used 2mg daily subcutaneous injection as the standard dose. This dose produced 15–20% visceral adipose tissue reduction at 26 weeks without significant adverse events in the majority of patients. Lower doses (1mg daily) were evaluated in earlier Phase 2 trials and showed reduced efficacy. Approximately 8–10% VAT reduction. Suggesting a dose-response relationship. Doses above 2mg daily were not evaluated in large trials due to concerns about growth hormone excess and glucose dysregulation risk.
Subcutaneous injection means the peptide is delivered into the subcutaneous fat layer. Not intramuscular, not intradermal. The correct injection site is the abdominal area, typically 2–3 inches lateral to the umbilicus (belly button), using a 27–30 gauge insulin syringe with a 0.5-inch needle. Pinch the skin to create a fold, insert the needle at a 45–90 degree angle, and inject slowly over 3–5 seconds. Do not aspirate. Aspiration is unnecessary for subcutaneous injections and increases risk of needle movement and tissue trauma.
Injection site rotation is critical. Repeated injections in the same site cause lipohypertrophy. Localized fat buildup and scar tissue formation that reduces peptide absorption. Rotate injection sites in a consistent pattern: right lower quadrant, left lower quadrant, right upper quadrant, left upper quadrant. Each site should rest at least 7 days between injections. Mark a rotation schedule if necessary. This is not optional.
Timing: clinical trials administered tesamorelin in the evening before bed, aligned with the body's natural nocturnal GH secretion peak. Growth hormone is secreted in pulsatile bursts, with the largest pulse occurring 60–90 minutes after sleep onset. Administering tesamorelin in the evening may enhance physiological alignment and minimize glucose impact during waking hours. Some users report better tolerance (fewer side effects, less morning joint stiffness) with evening injection, though no head-to-head timing trials exist.
Duration of use: clinical trials ran 26 weeks with demonstrated efficacy. Extension trials showed that discontinuation led to partial VAT regain, suggesting tesamorelin is a maintenance therapy rather than a one-time intervention. Users planning finite-duration protocols should expect 40–60% VAT regain within 6 months of stopping. For research applications exploring long-term visceral fat control, continuous or cyclical use (e.g., 12 weeks on, 4 weeks off) may be necessary, though no formal cycle studies exist in the published literature.
Receptor desensitization is a theoretical concern with chronic GHRH agonist use. Continuous stimulation of GPCR receptors can lead to downregulation. Reduced receptor expression on the cell surface. Which diminishes response over time. This is why pulsatile GH secretagogues like Ipamorelin or CJC1295 Ipamorelin 5MG 5MG are sometimes cycled or stacked. There is no published evidence that tesamorelin loses efficacy within 26 weeks, but anecdotal reports from long-term users (12+ months) suggest response may plateau. Periodic washout periods (4 weeks off every 12–16 weeks on) may preserve receptor sensitivity, though this remains speculative.
Tesamorelin Review 2026: Comparison Table
The table below compares tesamorelin to other peptide-based strategies for visceral fat reduction, growth hormone modulation, and metabolic support. Each option represents a distinct mechanism. GHRH agonism, ghrelin mimicry, GLP-1 agonism, and GH secretagogue stacking.
Tesamorelin
GHRH receptor agonist. Stimulates endogenous pulsatile GH release from pituitary
Visceral adipose tissue reduction in HIV lipodystrophy
2mg daily subcutaneous injection, evening preferred
15–20% VAT reduction at 26 weeks in Phase 3 RCTs
FDA-approved, multiple Phase 3 trials published in Lancet and AIDS journals
Gold standard for visceral fat reduction. Most robust clinical evidence, FDA approval, and safety profile. Ideal for targeted VAT loss without appetite suppression.
MK-677 (Ibutamoren)
Ghrelin receptor agonist. Stimulates GH and IGF-1 without pituitary GHRH pathway
Investigational for muscle wasting, bone density
25mg daily oral dosing
Limited VAT-specific data; increases lean mass but inconsistent fat loss
Phase 2 trials only; no FDA approval for any indication
Oral convenience is the primary advantage, but lacks VAT-specific efficacy data. Higher rates of water retention and increased appetite make fat loss outcomes inconsistent.
Ipamorelin
Growth hormone secretagogue. Stimulates GH release via ghrelin-independent pathway
Research peptide for GH modulation
200–300mcg per injection, 2–3× daily subcutaneous
No published VAT-specific trials; anecdotal fat loss reported
Preclinical and early-phase human trials only
Shorter half-life requires multiple daily injections. May synergize with GHRH agonists like tesamorelin in stacked protocols but lacks standalone VAT evidence.
Tirzepatide (GLP-1/GIP)
Dual GLP-1 and GIP receptor agonist. Slows gastric emptying, enhances insulin sensitivity
Type 2 diabetes and obesity (FDA-approved)
5–15mg weekly subcutaneous injection
15–22% total body weight reduction in SURMOUNT trials; VAT loss proportional to total weight loss
Phase 3 RCTs, FDA-approved
Produces greater total weight loss than tesamorelin but via appetite suppression and caloric deficit. Not selective VAT targeting. Best for patients needing whole-body fat loss and metabolic control.
CJC-1295 + Ipamorelin Stack
GHRH analog (CJC-1295) + ghrelin-independent GH secretagogue (Ipamorelin)
Synergistic GH pulse amplification
CJC-1295: 1–2mg weekly; Ipamorelin: 200–300mcg 2–3× daily
No published VAT-specific trials; anecdotal reports of enhanced body composition
Preclinical and anecdotal evidence only
Theoretical synergy between GHRH and non-ghrelin GH pathways. Lack of controlled human trials makes efficacy and safety profile speculative.
The core distinction: tesamorelin is the only peptide in this comparison table with FDA approval and published Phase 3 randomized controlled trial evidence specifically demonstrating visceral adipose tissue reduction. Other approaches may increase growth hormone levels or reduce total body weight, but visceral fat selectivity is unique to tesamorelin's GHRH mechanism.
For researchers exploring multi-pathway GH modulation, Real Peptides offers a comprehensive Tesamorelin Ipamorelin Growth Hormone Stack designed for investigational protocols requiring synergistic GH secretagogue activity. You can also explore our complete Shop All Peptides collection for additional research-grade compounds verified through third-party HPLC analysis.
Key Takeaways
Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that stimulates endogenous pulsatile GH secretion, producing 15–20% visceral adipose tissue reduction in 26-week Phase 3 randomized controlled trials.
The peptide must be reconstituted with bacteriostatic water and stored at 2–8°C after reconstitution. Temperature excursions above 8°C or improper reconstitution technique denature the peptide and eliminate efficacy.
Clinical dosing is 2mg daily via subcutaneous injection, preferably in the evening to align with physiological nocturnal GH secretion patterns.
Tesamorelin selectively reduces visceral fat without proportional subcutaneous fat loss. A mechanism distinct from GLP-1 agonists like tirzepatide, which produce total body weight reduction through appetite suppression.
Discontinuation leads to partial VAT regain (approximately 40% within 26 weeks), indicating tesamorelin functions as a maintenance therapy rather than a one-time intervention.
Injection site rotation across four abdominal quadrants is essential to prevent lipohypertrophy and maintain consistent peptide absorption across the treatment period.
What If: Tesamorelin Review 2026 Scenarios
What If I Accidentally Left Reconstituted Tesamorelin Out of the Refrigerator Overnight?
Discard the vial. Tesamorelin degrades rapidly at temperatures above 8°C. A single overnight temperature excursion (8–12 hours at room temperature) causes irreversible peptide bond hydrolysis that cannot be detected visually. The solution may appear clear and unchanged, but potency is compromised or eliminated entirely. There is no salvage protocol. Refrigeration is non-negotiable once reconstitution occurs.
What If I Experience Joint Pain or Carpal Tunnel Symptoms During Tesamorelin Use?
Joint pain and carpal tunnel syndrome are classic signs of elevated growth hormone levels causing fluid retention and soft tissue swelling. These symptoms occur in approximately 5–8% of tesamorelin users and are dose-dependent. If symptoms are mild, consider reducing dose to 1mg daily for 2 weeks before re-escalating. If symptoms are moderate to severe (numbness, pain interfering with daily function), discontinue tesamorelin and consult a healthcare provider. Unlike exogenous GH therapy, tesamorelin-induced symptoms typically resolve within 7–14 days of discontinuation due to the peptide's short half-life and lack of exogenous GH accumulation.
What If My Fasting Glucose Increases During Tesamorelin Treatment?
Growth hormone is a counter-regulatory hormone that opposes insulin action, promoting hepatic glucose output and reducing peripheral glucose uptake. Clinical trials showed mean fasting glucose increases of 4–6 mg/dL with tesamorelin, but individual responses vary. If fasting glucose rises above 110 mg/dL or HbA1c increases by more than 0.4%, consider baseline insulin sensitivity status. Patients with pre-existing insulin resistance or metabolic syndrome are at higher risk. Monitor fasting glucose weekly for the first month, then biweekly. If glucose dysregulation persists, discontinue tesamorelin and evaluate alternative interventions like Tirzepatide, which improves insulin sensitivity rather than opposing it.
What If I Don't See Visceral Fat Reduction After 12 Weeks on Tesamorelin?
Confirm reconstitution and storage protocol first. Improper handling is the most common cause of non-response. If protocol is correct, consider: (1) baseline visceral adipose tissue volume. Individuals with lower baseline VAT (<1000 cm2 on CT imaging) show smaller absolute reductions; (2) concurrent dietary intake. Tesamorelin does not suppress appetite, so caloric surplus will offset lipolytic effects; (3) injection technique. Subcutaneous delivery into scar tissue or lipohypertrophied areas reduces absorption. If all variables are controlled and no response is observed by 16 weeks, discontinue. Non-responders exist in all peptide protocols, and continuing ineffective treatment wastes time and resources.
The Evidence-Based Truth About Tesamorelin Review 2026
Here's the honest answer: tesamorelin is the only peptide with FDA approval and Phase 3 trial evidence specifically demonstrating visceral fat reduction. But that doesn't mean it's the right choice for everyone seeking fat loss. If your goal is total body weight reduction, appetite control, or metabolic disease management, GLP-1 receptor agonists like semaglutide or Tirzepatide outperform tesamorelin in every measurable outcome. Tesamorelin's value is selectivity. It targets visceral adipose tissue without suppressing appetite, without reducing subcutaneous fat, and without the gastrointestinal side effects that cause 30–40% of GLP-1 users to discontinue treatment.
The second truth: tesamorelin is not a standalone intervention. Clinical trials enrolled patients with HIV-associated lipodystrophy. A population with metabolic derangements that amplify visceral fat accumulation independent of caloric intake. In non-HIV populations, tesamorelin efficacy depends on concurrent dietary structure, resistance training to preserve lean mass during fat loss, and realistic expectations about magnitude of change. A 15% VAT reduction in someone with 2000 cm2 baseline VAT is a 300 cm2 absolute reduction. Clinically meaningful. A 15% reduction in someone with 600 cm2 baseline VAT is a 90 cm2 reduction. Less visually apparent and harder to measure without imaging.
The mechanism is real. The evidence is robust. But the application requires precision at every step. Reconstitution, storage, injection technique, site rotation, timing, and duration. Most "tesamorelin didn't work" reports trace back to procedural errors in the first 72 hours of use. If you're not prepared to follow pharmaceutical-grade handling protocols, you're not prepared to use tesamorelin effectively.
Real Peptides manufactures every peptide to pharmaceutical-grade standards, with small-batch synthesis ensuring batch-to-batch consistency and HPLC verification confirming >98% purity. When research outcomes depend on molecular precision, starting with high-purity peptides isn't optional. It's the baseline requirement. Explore our All Peptides collection for additional research-grade compounds synthesized to the same exacting standards.
Tesamorelin remains the gold standard for visceral fat reduction in 2026. Not because alternatives don't exist, but because no other compound has replicated its VAT-selective mechanism with equivalent clinical evidence. For the specific indication it was designed to address, it delivers. For broader fat-loss goals, consider whether selectivity or total weight reduction matters more to your protocol design.
Frequently Asked Questions
Tesamorelin stimulates growth hormone (GH) release from the pituitary gland, and visceral adipocytes (fat cells surrounding internal organs) express significantly higher densities of GH receptors compared to subcutaneous fat depots. When GH binds to these receptors, it activates hormone-sensitive lipase (HSL), the enzyme that breaks down stored triglycerides into free fatty acids for oxidation. The receptor density differential explains why Phase 3 trials showed 15–20% visceral adipose tissue reduction with minimal subcutaneous fat change — the mechanism is receptor-mediated, not systemic caloric deficit.
No. Sterile water lacks the 0.9% benzyl alcohol preservative that prevents bacterial growth in multi-dose vials. If you reconstitute with sterile water and store the vial for multiple injections, bacteria introduced during the first needle puncture will proliferate by the second or third draw, contaminating the entire vial. Bacteriostatic water is required for any multi-dose reconstitution protocol — using sterile water is a contamination risk that negates the entire investment.
A 26-week protocol requires approximately 182 days × 2mg per day = 364mg total tesamorelin. At current research-grade peptide pricing, this typically costs $1,200–$2,400 depending on supplier and purity verification standards. This does not include bacteriostatic water, syringes, alcohol prep pads, or optional CT imaging to measure visceral adipose tissue changes. Compounded pharmaceutical tesamorelin through prescribers ranges $400–$800 per month, making a 26-week course $2,400–$4,800.
No — tesamorelin stimulates your body’s own pulsatile GH release rather than replacing it with continuous exogenous GH. This distinction is critical. Exogenous GH produces sustained elevated GH levels throughout the day, leading to insulin resistance, joint pain, carpal tunnel syndrome, and edema in 20–40% of users. Tesamorelin produces transient GH pulses that resolve within hours, mimicking natural physiology. Clinical trials showed joint pain in only 5–8% of tesamorelin users, and glucose increases averaged 4–6 mg/dL versus 15–25 mg/dL with exogenous GH.
Extension trials published in AIDS (2012) found that patients who discontinued tesamorelin after 26 weeks regained approximately 40% of lost visceral adipose tissue within the next 26 weeks. The rate of regain depends on dietary intake, activity level, and underlying metabolic health — patients who maintained structured resistance training and caloric control regained less. Tesamorelin does not permanently reset visceral fat set point; it is a maintenance therapy that requires continued use or structured lifestyle intervention to preserve results after discontinuation.
Yes, but it is off-label use. The FDA approved tesamorelin specifically for HIV-associated lipodystrophy, but the mechanism — GHRH receptor activation leading to GH-mediated lipolysis — is not HIV-specific. Several smaller trials have evaluated tesamorelin in non-HIV populations with metabolic syndrome and showed similar visceral fat reductions, though these were Phase 2 studies with fewer than 100 participants. Prescribers may offer it off-label, but insurance coverage is unlikely outside the FDA-approved indication.
If you miss a single dose, administer it as soon as you remember within the same 24-hour period and continue your regular schedule the next day. If more than 24 hours have passed, skip the missed dose and resume on your next scheduled day — do not double-dose. Missing 2–3 consecutive doses may temporarily reduce GH and IGF-1 elevation, slowing visceral fat reduction for that week, but it does not negate prior progress. Consistency matters more than perfection over a 26-week protocol.
Clinical trials evaluated continuous daily use for 26 weeks without planned washout periods, and efficacy was maintained throughout. However, no published trials extend beyond 52 weeks of continuous use, so long-term receptor desensitization risk remains theoretical. Some advanced users implement 12 weeks on, 4 weeks off cycling based on GPCR downregulation theory, but this is speculative — no controlled trials exist comparing continuous versus cycled protocols. For research durations under 26 weeks, continuous daily dosing is supported by clinical evidence.
Tesamorelin is a GHRH receptor agonist — it directly stimulates the pituitary cells that release growth hormone. CJC-1295 is also a GHRH analog but with an extended half-life due to Drug Affinity Complex (DAC) modification, causing prolonged receptor occupancy. Ipamorelin is a ghrelin mimetic that stimulates GH release through a different receptor pathway entirely. The clinical distinction: tesamorelin has Phase 3 trial data, FDA approval, and proven visceral fat efficacy. CJC-1295 and ipamorelin lack large-scale human trials demonstrating VAT reduction — their use is based on preclinical data and anecdotal reports, not randomized controlled evidence.
Baseline fasting glucose and HbA1c testing are strongly recommended because growth hormone opposes insulin action and can worsen glycemic control in patients with pre-existing insulin resistance or diabetes. Baseline IGF-1 levels are optional but useful for confirming the peptide is producing expected endocrine response (IGF-1 should increase 35–50% within 2–4 weeks). Liver function tests (ALT, AST) are prudent if baseline liver disease is suspected, as visceral fat reduction can transiently elevate liver enzymes as fat is mobilized from hepatic tissue.